Market Research Life Sciences Market Research Pharmaceuticals Market Research Antibiotic Market Research

Perinatal Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Infection (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Others); By D

Best Price Guarantee Length Publisher Published Date SKU
from $4,850 400 Pages BlueWeave Consulting April, 2023 BLWC17899945
Best Price Guarantee
Price from $4,850
Length 400 Pages
Publisher BlueWeave Consulting
Published Date April, 2023
SKU BLWC17899945

Perinatal Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Infection (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Others); By Diagnosis (Maternal Test, Neonatal Test, Others); By Treatment (Antibiotics, Antiviral, Antiretroviral, Others); By Route of Administration (Oral, Parenteral, Others); By End User (Hospitals, Homecare, Specialty Clinics, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)


Global Perinatal Infections Market Set to Grow at Steady CAGR of 7.3% During 2023–2029


Global perinatal infections market is gaining traction because of the increasing cases of HIV and incidences of perinatal infections.



BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, expects the global perinatal infections market size to grow at a steady CAGR of 7.3% during the forecast period between 2023 and 2029. High birth rates and an increasing yearly birth rate, as well as unsanitary circumstances around expectant mothers, particularly in developing countries, are major growth drivers for the global perinatal infections market. During the period in analysis, it is forecast that perinatal infections would continue to rise in prevalence due to the rising rate of preterm births.

Global Perinatal Infections Market – Overview



Perinatal infections are infections that can be passed from the person giving birth to the newborn during pregnancy, childbirth, or the first few hours following birth. Because newborns, especially those born preterm, have a limited capacity for symptom expression, even little variations from the norm should be taken as a sign of bacterial illness. Infections like the flu, vaginal yeast infections, dermatitis, herpes, uterine infections, group B streptococcus (GBS), bacterial vaginosis (BV), and listeria are frequently seen during pregnancy.

Global Perinatal Infections Market – By End User



Based on end user, the global Perinatal Infections market is segmented into hospitals, homecare, specialty clinics, and others. The hospital segment accounts for the highest market share, as hospitals are considered the safest settings for delivery. According to the National Academics, a vast majority of Americans, around 98.4%, give birth in a hospital, which contributes to the segment’s growth. However, homecare and specialty clinics are also projected to register a high growth rate during the forecast period owing to the growing number of pregnant people opting to give birth outside of hospitals, either at home or in specialized birthing facilities known as birth centers.

Impact of COVID-19 on Global Perinatal Infections Market

According to research published in the National Center for Biotechnology Information, no specific or convincing evidence exists to support the notion that SARS-CoV and MERS-CoV are vertically transmitted. Similarly, there is not enough evidence at this time to demonstrate that COVID-19 is transmitted vertically. However, a newborn delivered to a pregnant person who had COVID-19 was said to have higher IgM antibody levels to SARS-CoV-2 in blood two hours after delivery, indicating that COVID-19 may have the potential for vertical transmission. This resulted in significant growth in the overall global perinatal infections market.

Competitive Landscape

Major players operating in the global perinatal infections market include Merck KGaA, Beckman Coulter Inc., BIOMERIEUX, Bio-Rad Laboratories, Inc, Danaher, Hologic Inc., Gilead Sciences, Inc., Emcure Pharmaceuticals Limited., Cipla Inc., Hetero, Bausch Health Companies Inc., Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, and Sun Pharmaceutical Industries Ltd.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Perinatal Infections Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Perinatal Infections Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.


1. Research Framework
1.1. Research Objective
1.2. Infection Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Perinatal Infections Market Insights
3.1. Industry Value Chain Analysis
3.1.1. DROC Analysis
3.1.2. Growth Drivers
3.1.2.1. Increased Cases of HIV
3.1.2.2. Increasing Incidence of Perinatal Infections
3.1.3. Restraints
3.1.3.1. Lack of skilled professionals
3.1.4. Opportunities
3.1.4.1. Increasing Demand for Retail Pharmacies
3.1.5. Challenges
3.1.5.1. High Cost Involved in Treatment
3.2. Technological Advancement/Recent Developments
3.3. Regulatory Framework
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrants
3.4.4. Threat of Substitutes
3.4.5. Intensity of Rivalry
4. Global Perinatal Infections Market Overview
4.1. Market Size & Forecast, 2019–2029
4.1.1. By Value (USD Million)
4.2. Market Share & Forecast
4.2.1. By Infection
4.2.1.1. Cytomegalovirus Infection
4.2.1.2. Enterovirus Infection
4.2.1.3. Genital Herpes
4.2.1.4. Gonorrhoea
4.2.1.5. Human Immunodeficiency Virus
4.2.1.6. Others
4.2.2. By Diagnosis
4.2.2.1. Maternal Test
4.2.2.2. Neonatal Test
4.2.2.3. Others
4.2.3. By Treatment
4.2.3.1. Antibiotics
4.2.3.2. Antiviral
4.2.3.3. Antiretroviral
4.2.3.4. Others
4.2.4. By Route of Administration
4.2.4.1. Oral
4.2.4.2. Parenteral
4.2.4.3. Others
4.2.5. By End User
4.2.5.1. Hospitals
4.2.5.2. Homecare
4.2.5.3. Specialty Clinics
4.2.5.4. Others
4.2.6. By Region
4.2.6.1. North America
4.2.6.2. Europe
4.2.6.3. Asia Pacific (APAC)
4.2.6.4. Latin America (LATAM)
4.2.6.5. Middle East and Africa (MEA)
5. North America Perinatal Infections Market
5.1. Market Size & Forecast, 2019–2029
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Infection
5.2.2. By Diagnosis
5.2.3. By Treatment
5.2.4. By Route of Administration
5.2.5. By End User
5.2.6. By Country
5.2.6.1. United States
5.2.6.1.1. By Infection
5.2.6.1.2. By Diagnosis
5.2.6.1.3. By Treatment
5.2.6.1.4. By Route of Administration
5.2.6.1.5. By End User
5.2.6.2. Canada
5.2.6.2.1. By Infection
5.2.6.2.2. By Diagnosis
5.2.6.2.3. By Treatment
5.2.6.2.4. By Route of Administration
5.2.6.2.5. By End User
6. Europe Perinatal Infections Market
6.1. Market Size & Forecast, 2019–2029
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Infection
6.2.2. By Diagnosis
6.2.3. By Treatment
6.2.4. By Route of Administration
6.2.5. By End User
6.2.6. By Country
6.2.6.1. Germany
6.2.6.1.1. By Infection
6.2.6.1.2. By Diagnosis
6.2.6.1.3. By Treatment
6.2.6.1.4. By Route of Administration
6.2.6.1.5. By End User
6.2.6.2. UK
6.2.6.2.1. By Infection
6.2.6.2.2. By Diagnosis
6.2.6.2.3. By Treatment
6.2.6.2.4. By Route of Administration
6.2.6.2.5. By End User
6.2.6.3. Italy
6.2.6.3.1. By Infection
6.2.6.3.2. By Diagnosis
6.2.6.3.3. By Treatment
6.2.6.3.4. By Route of Administration
6.2.6.3.5. By End User
6.2.6.4. France
6.2.6.4.1. By Infection
6.2.6.4.2. By Diagnosis
6.2.6.4.3. By Treatment
6.2.6.4.4. By Route of Administration
6.2.6.4.5. By End User
6.2.6.5. Spain
6.2.6.5.1. By Infection
6.2.6.5.2. By Diagnosis
6.2.6.5.3. By Treatment
6.2.6.5.4. By Route of Administration
6.2.6.5.5. By End User
6.2.6.6. The Netherlands
6.2.6.6.1. By Infection
6.2.6.6.2. By Diagnosis
6.2.6.6.3. By Treatment
6.2.6.6.4. By Route of Administration
6.2.6.6.5. By End User
6.2.6.7. Rest of Europe
6.2.6.7.1. By Infection
6.2.6.7.2. By Diagnosis
6.2.6.7.3. By Treatment
6.2.6.7.4. By Route of Administration
6.2.6.7.5. By End User
7. Asia-Pacific Perinatal Infections Market
7.1. Market Size & Forecast, 2019–2029
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Infection
7.2.2. By Diagnosis
7.2.3. By Treatment
7.2.4. By Route of Administration
7.2.5. By End User
7.2.6. By Country
7.2.6.1. China
7.2.6.1.1. By Infection
7.2.6.1.2. By Diagnosis
7.2.6.1.3. By Treatment
7.2.6.1.4. By Route of Administration
7.2.6.1.5. By End User
7.2.6.2. India
7.2.6.2.1. By Infection
7.2.6.2.2. By Diagnosis
7.2.6.2.3. By Treatment
7.2.6.2.4. By Route of Administration
7.2.6.2.5. By End User
7.2.6.3. Japan
7.2.6.3.1. By Infection
7.2.6.3.2. By Diagnosis
7.2.6.3.3. By Treatment
7.2.6.3.4. By Route of Administration
7.2.6.3.5. By End User
7.2.6.4. South Korea
7.2.6.4.1. By Infection
7.2.6.4.2. By Diagnosis
7.2.6.4.3. By Treatment
7.2.6.4.4. By Route of Administration
7.2.6.4.5. By End User
7.2.6.5. Australia & New Zealand
7.2.6.5.1. By Infection
7.2.6.5.2. By Diagnosis
7.2.6.5.3. By Treatment
7.2.6.5.4. By Route of Administration
7.2.6.5.5. By End User
7.2.6.6. Indonesia
7.2.6.6.1. By Infection
7.2.6.6.2. By Diagnosis
7.2.6.6.3. By Treatment
7.2.6.6.4. By Route of Administration
7.2.6.6.5. By End User
7.2.6.7. Malaysia
7.2.6.7.1. By Infection
7.2.6.7.2. By Diagnosis
7.2.6.7.3. By Treatment
7.2.6.7.4. By End User
7.2.6.8. Singapore
7.2.6.8.1. By Infection
7.2.6.8.2. By Diagnosis
7.2.6.8.3. By Treatment
7.2.6.8.4. By Route of Administration
7.2.6.8.5. By End User
7.2.6.9. Philippines
7.2.6.9.1. By Infection
7.2.6.9.2. By Diagnosis
7.2.6.9.3. By Treatment
7.2.6.9.4. By Route of Administration
7.2.6.9.5. By End User
7.2.6.10. Vietnam
7.2.6.10.1. By Infection
7.2.6.10.2. By Diagnosis
7.2.6.10.3. By Treatment
7.2.6.10.4. By Route of Administration
7.2.6.10.5. By End User
7.2.6.11. Rest of APAC
7.2.6.11.1. By Infection
7.2.6.11.2. By Diagnosis
7.2.6.11.3. By Treatment
7.2.6.11.4. By Route of Administration
7.2.6.11.5. By End User
8. Latin America Perinatal Infections Market
8.1. Market Size & Forecast, 2019–2029
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Infection
8.2.2. By Diagnosis
8.2.3. By Treatment
8.2.4. By Route of Administration
8.2.5. By End User
8.2.6. By Country
8.2.6.1. Brazil
8.2.6.1.1. By Infection
8.2.6.1.2. By Diagnosis
8.2.6.1.3. By Treatment
8.2.6.1.4. By Route of Administration
8.2.6.1.5. By End User
8.2.6.2. Mexico
8.2.6.2.1. By Infection
8.2.6.2.2. By Diagnosis
8.2.6.2.3. By Treatment
8.2.6.2.4. By Route of Administration
8.2.6.2.5. By End User
8.2.6.3. Argentina
8.2.6.3.1. By Infection
8.2.6.3.2. By Diagnosis
8.2.6.3.3. By Treatment
8.2.6.3.4. By Route of Administration
8.2.6.3.5. By End User
8.2.6.4. Peru
8.2.6.4.1. By Infection
8.2.6.4.2. By Diagnosis
8.2.6.4.3. By Treatment
8.2.6.4.4. By Route of Administration
8.2.6.4.5. By End User
8.2.6.5. Rest of LATAM
8.2.6.5.1. By Infection
8.2.6.5.2. By Diagnosis
8.2.6.5.3. By Treatment
8.2.6.5.4. By Route of Administration
8.2.6.5.5. By End User
9. Middle East & Africa Perinatal Infections Market
9.1. Market Size & Forecast, 2019–2029
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Infection
9.2.2. By Diagnosis
9.2.3. By Treatment
9.2.4. By Route of Administration
9.2.5. By End User
9.2.6. By Country
9.2.6.1. Saudi Arabia
9.2.6.1.1. By Infection
9.2.6.1.2. By Diagnosis
9.2.6.1.3. By Treatment
9.2.6.1.4. By Route of Administration
9.2.6.1.5. By End User
9.2.6.2. UAE
9.2.6.2.1. By Infection
9.2.6.2.2. By Diagnosis
9.2.6.2.3. By Treatment
9.2.6.2.4. By Route of Administration
9.2.6.2.5. By End User
9.2.6.3. Qatar
9.2.6.3.1. By Infection
9.2.6.3.2. By Diagnosis
9.2.6.3.3. By Treatment
9.2.6.3.4. By Route of Administration
9.2.6.3.5. By End User
9.2.6.4. Kuwait
9.2.6.4.1. By Infection
9.2.6.4.2. By Diagnosis
9.2.6.4.3. By Treatment
9.2.6.4.4. By Route of Administration
9.2.6.4.5. By End User
9.2.6.5. South Africa
9.2.6.5.1. By Infection
9.2.6.5.2. By Diagnosis
9.2.6.5.3. By Treatment
9.2.6.5.4. By Route of Administration
9.2.6.5.5. By End User
9.2.6.6. Nigeria
9.2.6.6.1. By Infection
9.2.6.6.2. By Diagnosis
9.2.6.6.3. By Treatment
9.2.6.6.4. By Route of Administration
9.2.6.6.5. By End User
9.2.6.7. Algeria
9.2.6.7.1. By Infection
9.2.6.7.2. By Diagnosis
9.2.6.7.3. By Treatment
9.2.6.7.4. By Route of Administration
9.2.6.7.5. By End User
9.2.6.8. Rest of MEA
9.2.6.8.1. By Infection
9.2.6.8.2. By Diagnosis
9.2.6.8.3. By Treatment
9.2.6.8.4. By Route of Administration
9.2.6.8.5. By End User
10. Competitive Landscape
10.1.
List of Key Players and Their Offerings
10.2. Global Perinatal Infections Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Perinatal Infections Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
12.1. Merck KGaA
12.2. Beckman Coulter Inc.
12.3. BIOMERIEUX
12.4. Bio-Rad Laboratories, Inc
12.5. Danaher
12.6. Hologic Inc.
12.7. Gilead Sciences, Inc.
12.8. Emcure Pharmaceuticals Limited.
12.9. Cipla Inc.
12.10. Hetero
12.11. Bausch Health Companies Inc.
12.12. Johnson & Johnson Private Limited
12.13. Mylan N.V.
12.14. Teva Pharmaceutical Industries Ltd.
12.15. Sanofi
12.16. Novartis AG
12.17. Sun Pharmaceutical Industries Ltd.
12.18. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations

$4,850
$5,750
$8,150

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings